Drug intelligence / Profile preview

Shenyang Pharma Univ. ALK compound B10

Development stage: Unknown
Lead developer: Shenyang Pharmaceutical University

Overview

Shenyang Pharma Univ. ALK compound B10: sourced facts only. name: "These results indicated that B10 was a potent ALK inhibitor for ALKG1202R mutation treatment and deserved for further investigation." [PMID:35576654]; target: "These results indicated that B10 was a potent ALK inhibitor for ALKG1202R mutation treatment and deserved for further investigation." [PMID:35576654]; developer: "School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China." [PMID:35576654]

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on Shenyang Pharma Univ. ALK compound B10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyang Pharma Univ. ALK compound B10.